AptarGroup, Inc. Q1 2002 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2002. AptarGroup, Inc. operates in the packaging components industry, developing and selling consumer product dispensing systems. The company is organized into two reportable segments: Dispensing Systems (non-aerosol pumps, closures, valves) and SeaquistPerfect (aerosol valves and accessories). Operations are global, with significant exposure to foreign currency fluctuations, particularly the Euro.
Key Financial Metrics
| Metric (in thousands) | Q1 2002 | Q1 2001 |
|---|---|---|
| Net Sales | $218,707 | $232,899 |
| Operating Income | $22,272 | $31,274 |
| Net Income | $13,275 | $18,110 |
| Diluted EPS | $0.36 | $0.50 |
| Operating Cash Flow | $29,958 | $29,012 |
| Cash and Equivalents | $52,348 | $55,689 |
| Total Debt (Current + Long-Term) | $250,364 | N/A |
| Net Debt to Capitalization | 29.7% | 30.4% (Dec 2001) |
Note: Total Debt calculated as Current maturities ($12,708) + Long-Term Obligations ($237,656).
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 6% ($14.2 million) year-over-year. Core sales (excluding currency effects) declined 4%. The decrease was driven by a sharp drop in fragrance/cosmetic sales and a stronger U.S. dollar, partially offset by strong pharmaceutical sales.
- Profitability Impact: Operating income fell 29% to $22.3 million. This decline was significantly impacted by a one-time $4.2 million pre-tax charge for a patent dispute settlement recorded in Q1 2002. Excluding this charge, operating income would have been $26.4 million.
- Cost Structure: Cost of sales as a percentage of net sales increased to 63.9% from 62.8%, attributed to underutilized fixed costs due to lower pump sales and price pressure in the closures business.
- Accounting Changes: The company adopted SFAS No. 142, ceasing goodwill amortization effective January 1, 2002. This resulted in no goodwill amortization expense in Q1 2002 compared to $0.9 million in Q1 2001.
Guidance, Outlook, and Risks
- Q2 2002 Guidance: Management expects diluted earnings per share in the range of $0.48 to $0.54, excluding Strategic Initiative charges. This compares to $0.41 reported in Q2 2001.
- Full Year Outlook: The company targets double-digit earnings growth for the full year 2002 on a comparable basis over 2001.
- Market Outlook: Demand for low-to-mid-range fragrance/cosmetic products is expected to improve in Q2, while the upper-end market remains weak. Pharmaceutical sales are expected to remain strong.
- Risks and Contingencies:
- Currency Risk: A strengthening U.S. dollar has a dilutive effect on translated foreign earnings.
- Patent Dispute: A settlement was reached in May 2002 (subsequent event) for a $4.2 million charge, avoiding a trial.
- Strategic Initiative: Ongoing restructuring to improve efficiency, involving plant closures in the U.S. and consolidation in Italy, with total expected charges of approximately $10 million.
Investor Verification Checklist
- Verify the impact of the $4.2 million patent dispute settlement on Q1 earnings and confirm the payment schedule (expected in Q2 2002).
- Assess the sustainability of the pharmaceutical market growth which offset declines in the fragrance/cosmetic sector.
- Monitor the progress of the Strategic Initiative restructuring costs and the realization of projected cost savings.
- Review the foreign currency exposure given the significant portion of sales (55%) generated in Europe and the impact of the strong U.S. dollar.
- Confirm the company's ability to meet the double-digit full-year earnings growth target amidst current market headwinds.